In lat­est deal, Melin­ta ex­e­cutes $270M pact to buy out Med­i­cines Co’s in­fec­tious dis­ease group

As promised, The Med­i­cines Com­pa­ny has found a buy­er for its in­fec­tious dis­ease unit. Wheel­ing and deal­ing its way through the year, Melin­ta Ther­a­peu­tics has stepped up with an agree­ment to ac­quire the group for $270 mil­lion in cash and some stock, clear­ing the way for The Med­i­cines Com­pa­ny to con­cen­trate on a new PC­SK9 ther­a­py.

The Med­i­cines Com­pa­ny $MD­CO — which has been re­struc­tur­ing over the past two years — al­so gets tiered roy­al­ties rang­ing up to 25% on Vabomere, Or­bac­tiv and Minocin IV. And Melin­ta moves up the lad­der in the an­tibi­otics field, just three months af­ter strik­ing a deal to merge trou­bled Cem­pra $CEMP in­to the com­pa­ny, tak­ing over its an­tibi­otics pipeline and one ap­proved ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.